全文获取类型
收费全文 | 212754篇 |
免费 | 15776篇 |
国内免费 | 5799篇 |
专业分类
耳鼻咽喉 | 2833篇 |
儿科学 | 3287篇 |
妇产科学 | 2595篇 |
基础医学 | 28593篇 |
口腔科学 | 4733篇 |
临床医学 | 22579篇 |
内科学 | 33833篇 |
皮肤病学 | 5194篇 |
神经病学 | 14125篇 |
特种医学 | 10566篇 |
外国民族医学 | 29篇 |
外科学 | 24877篇 |
综合类 | 16896篇 |
现状与发展 | 21篇 |
一般理论 | 45篇 |
预防医学 | 14620篇 |
眼科学 | 5150篇 |
药学 | 20731篇 |
112篇 | |
中国医学 | 7452篇 |
肿瘤学 | 16058篇 |
出版年
2024年 | 418篇 |
2023年 | 2087篇 |
2022年 | 5689篇 |
2021年 | 8296篇 |
2020年 | 5212篇 |
2019年 | 5473篇 |
2018年 | 6215篇 |
2017年 | 5805篇 |
2016年 | 6549篇 |
2015年 | 9277篇 |
2014年 | 11355篇 |
2013年 | 12872篇 |
2012年 | 18622篇 |
2011年 | 18596篇 |
2010年 | 12281篇 |
2009年 | 10341篇 |
2008年 | 13072篇 |
2007年 | 12526篇 |
2006年 | 11320篇 |
2005年 | 10205篇 |
2004年 | 8307篇 |
2003年 | 7417篇 |
2002年 | 6364篇 |
2001年 | 4888篇 |
2000年 | 4129篇 |
1999年 | 3049篇 |
1998年 | 1352篇 |
1997年 | 1135篇 |
1996年 | 824篇 |
1995年 | 702篇 |
1994年 | 611篇 |
1993年 | 505篇 |
1992年 | 943篇 |
1991年 | 898篇 |
1990年 | 822篇 |
1989年 | 733篇 |
1988年 | 593篇 |
1987年 | 586篇 |
1986年 | 447篇 |
1985年 | 462篇 |
1984年 | 320篇 |
1983年 | 248篇 |
1982年 | 170篇 |
1981年 | 202篇 |
1980年 | 157篇 |
1979年 | 292篇 |
1978年 | 208篇 |
1976年 | 157篇 |
1975年 | 178篇 |
1974年 | 171篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
131.
132.
133.
134.
Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. 总被引:11,自引:1,他引:10 下载免费PDF全文
C M Wei C H Kim V M Miller J C Burnett Jr 《The Journal of clinical investigation》1993,92(4):2048-2052
This study reports the cardiovascular and renal actions of a novel and newly synthesized 27-amino acid peptide termed vasonatrin peptide (VNP). VNP is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). This synthetic peptide possesses the 22-amino acid structure of CNP, which is a cardiovascular selective peptide of endothelial origin and is structurally related to ANP. VNP also possesses the five-amino acid COOH terminus of ANP. The current study demonstrates both in vitro and in vivo that VNP possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. 相似文献
135.
136.
Tamoxifen, an antiestrogen with efficacy in treatment of both estrogen receptor-positive and negative breast tumors, may be immunomodulatory. We tested tamoxifen's ability to augment the antitumor activity of interleukin-2 (IL-2), a lymphokine capable of expanding and activating lymphocytes, in the treatment of established pulmonary metastases of the weakly immunogenic murine fibrosarcoma MCA-106. Age-matched C57BL/6 female mice bearing pulmonary metastases induced by a tail vein injection of MCA-106 tumor suspension (5 x 10(5) cells/mouse) were treated from days 3 through 12 with intraperitoneal saline solution or IL-2 (50,000 units twice a day). Half of the mice in each group received plain and the remainder received tamoxifen-treated (2 units/ml) drinking water ad libitum for the duration of the experiment. All mice were killed on day 18 for enumeration of pulmonary metastases. Compared with saline-treated control mice, IL-2 and tamoxifen reduced metastases by 66% (p less than 0.0002) and 30% (p less than 0.005), respectively. IL-2 and tamoxifen combined reduced metastases 95% (p less than 0.0002), significantly better than did IL-2 (p less than 0.02) or tamoxifen (p less than 0.0003) alone. In vitro, tamoxifen inhibited proliferation of the weakly estrogen receptor-positive MCA-106 tumor by approximately 30%. Tamoxifen had no effect on the generation of 3-day IL-2-activated lymphocyte cytotoxicity against both natural killer-sensitive (YAC) and natural killer-resistant (MCA-106) target cells. Both YAC and MCA-106 tumor became more resistant to lysis with increased concentration of tamoxifen. This is the first demonstration of in vivo potentiation of IL-2 antitumor activity by tamoxifen and suggests its possible use clinically. 相似文献
137.
PURPOSETo evaluate the efficacy, safety, and results of direct thrombolytic therapy in intracranial dural sinus thrombosis by infusion of alteplase (recombinant tissue plasminogen activator).METHODSNine patients were treated during a 2-year period for intracranial dural sinus thrombosis. A microcatheter was placed directly into the thrombus in the dural sinus via the transfemoral route. Thrombolysis was initiated with a rapid injection of 10 mg of alteplase over 10 minutes, followed in 3 hours by a continuous infusion of 50 mg, then a continuous infusion at 5 mg per hour until complete thrombolysis or a total dose of 100 mg per day had been reached. Repeat thrombolysis was tried the following day if complete recanalization did not occur at 100 mg per day.RESULTSSuccessful recanalization with improvement of symptoms was achieved in all cases. Time required for complete thrombolysis was between 8 and 43 hours. The total dose of alteplase ranged from 50 to 300 mg. Complications of a small intrapelvic hemorrhage and oozing at a femoral puncture site occurred in separate cases, but were not related to the amount of infused alteplase. MR venograms obtained 1 to 4 weeks after the procedure showed no evidence of reocclusion of the dural sinuses.CONCLUSIONDirect fibrinolytic therapy with alteplase is safe, fast, and effective in treating dural sinus thrombosis. However, to prevent hemorrhagic complications, further studies are required to determine its optimal dose and proper rate of administration. 相似文献
138.
Jin Woo Kim M.D. Ho Shik Kim M.D. In Kyung Kim M.D. Mee Ran Kim M.D. Eun Young Cho B.S. Heung Kee Kim M.D. Joon Mo Lee M.D. Sung Eun Namkoong M.D. 《Gynecologic oncology》1998,69(3):230-236
Transforming growth factor-β1 (TGF-β1) is known to be a potent growth inhibitor for many cell types, including most epithelial cells. In skin keratinocytes, TGF-β1 has been shown to inhibit growth and to rapidly reduce c-mycexpression. However, the molecular mechanism of TGF-β1 action on cell growth of cervical carcinoma has not yet been elucidated. We thus assessed the effect of TGF-β1 on the growth of cervical carcinoma cell lines. Two cervical squamous carcinoma cell lines, CUMC-3 and CUMC-6, were incubated with varying concentrations of TGF-β1, and growth inhibition was evaluated with tetrazolium-based colorimetric assay. After culture in TGF-β1 for 24 h, inhibition of growth was detected in a dose-dependent manner at concentrations of 0.1–10 ng/ml in both cell lines. This effect of TGF-β1 on cultured carcinoma cells was associated with apoptotic process including oligonucleosomal ladder DNA and apoptotic body formations. Northern blot analysis revealed c-mycmRNA expression was suppressed by 10 ng/ml of TGF-β1 following 3 h of treatment in both cell lines. Western blot analysis showed that the level of p27Kip1protein was increased after TGF-β1 treatment in both cell lines. These results suggest that the mechanisms by which TGF-β1 inhibits the growth of cervical carcinoma are complex and may include effects on down-regulation of c-mycgene, and overexpression of p27Kip1protein. 相似文献
139.
G. Lee P. S. Choi D. S. Woo H. C. Park H. J. Kim Y. H. Lee 《Journal of Korean medical science》1998,13(2):215-218
Emphysematous cystitis is characterized by gas collection within the bladder wall and lumen. We report two cases of emphysematous cystitis of the urinary bladder in a 67-year-old and a 63-year-old women. They presented with bladder irritation symptoms such as dysuria, hematuria and frequency. Urinalysis showed pyuria. Cystoscopic examination revealed that bladder mucosa was studded with vesicles varying in size and arranged in clumps. CT scans of the pelvis showed mottled gas bubbles within the bladder. They were treated with antibiotics. Four days after the treatment, the symptoms subsided and plain abdominal film showed no evidence of gas shadows in the pelvic cavity. 相似文献
140.
Amrik Sahota Min Yang Sujuan Gao Siu L. Hui Olusegun Baiyewu Oyewusi Gureje Steven Oluwole Adesola Ogunniyi Kathleen S. Hall Hugh C. Hendrie 《Annals of neurology》1997,42(4):659-661
As a part of our ongoing study on Alzheimer's disease (AD) in elderly African Americans, we obtained clinical assessment and apolipoprotein E (ApoE) genotype data on 288 individuals (including 60 with AD). The ApoE σ4 allele frequency was significantly increased in AD patients compared with controls. The age-adjusted odds ratio (OR) for AD in σ4 homozygotes was 4.83 (95% confidence interval [CI], 1.71–13.64) compared with the σ3/σ3 genotype, but the OR for AD with the σ3/σ4 genotype did not reach significance (1.20; 95% CI, 0.58–2.45). These findings suggest that the association between ApoE σ4 and AD is weaker in African Americans than in whites. 相似文献